Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms.
Papatheodoridi M, De Ledinghen V, Lupsor-Platon M, Bronte F, Boursier J, Elshaarawy O, Marra F, Thiele M, Markakis G, Payance A, Brodkin E, Castera L, Papatheodoridis G, Krag A, Arena U, Mueller S, Cales P, Calvaruso V, Delamarre A, Pinzani M, Tsochatzis EA. Papatheodoridi M, et al. Among authors: calvaruso v. J Hepatol. 2024 Oct;81(4):590-599. doi: 10.1016/j.jhep.2024.05.021. Epub 2024 May 23. J Hepatol. 2024. PMID: 38789011
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis.
Di Marco V, Covolo L, Calvaruso V, Levrero M, Puoti M, Suter F, Gaeta GB, Ferrari C, Raimondo G, Fattovich G, Santantonio T, Alberti A, Bruno R, Mussini C, Mondelli M, Donato F, Craxì A; Multicenter Italian Group for the Study of Hepatitis C. Di Marco V, et al. Among authors: calvaruso v. J Viral Hepat. 2013 Nov;20(11):790-800. doi: 10.1111/jvh.12106. Epub 2013 Sep 15. J Viral Hepat. 2013. PMID: 24168258
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. Di Maio VC, et al. Among authors: calvaruso v. Liver Int. 2017 Apr;37(4):514-528. doi: 10.1111/liv.13327. Epub 2017 Jan 20. Liver Int. 2017. PMID: 28105744
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.
Andriulli A, Nardi A, Di Marco V, Ippolito AM, Gavrila C, Aghemo A, Di Paolo D, Squadrito G, Grassi E, Calvaruso V, Valvano MR, Brancaccio G, Craxi A, Angelico M; Collaborators. Andriulli A, et al. Among authors: calvaruso v. Dig Liver Dis. 2014 Sep;46(9):818-25. doi: 10.1016/j.dld.2014.05.015. Epub 2014 Jun 20. Dig Liver Dis. 2014. PMID: 24953209
Immunological alterations in hepatitis C virus infection.
Calvaruso V, Craxì A. Calvaruso V, et al. World J Gastroenterol. 2013 Dec 21;19(47):8916-23. doi: 10.3748/wjg.v19.i47.8916. World J Gastroenterol. 2013. PMID: 24379616 Free PMC article. Review.
Critically ill patients with cirrhosis and low serum sodium.
Cholongitas E, Calvaruso V, Betrosian A, Senzolo M, Shaw S, O'Beirne J, Burroughs AK. Cholongitas E, et al. Among authors: calvaruso v. J Clin Gastroenterol. 2010 Aug;44(7):523-4; author reply 524-5. doi: 10.1097/MCG.0b013e3181d6b917. J Clin Gastroenterol. 2010. PMID: 20216426 Free article. No abstract available.
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program.
Bruno S, Bollani S, Zignego AL, Pascasio JM, Magni C, Ciancio A, Caremani M, Mangia A, Marenco S, Piovesan S, Chemello L, Babudieri S, Moretti A, Gea F, Colletta C, Perez-Alvarez R, Forns X, Larrubia JR, Arenas J, Crespo J, Calvaruso V, Ceccherini Silberstein F, Maisonneuve P, Craxì A, Calleja JL; Italian and Spanish (IAS)-BoC Study Group. Bruno S, et al. Among authors: calvaruso v. J Viral Hepat. 2015 May;22(5):469-80. doi: 10.1111/jvh.12342. Epub 2014 Oct 14. J Viral Hepat. 2015. PMID: 25311757 Free article.
158 results